Publicaciones en colaboración con investigadores/as de Weill Cornell Medical College in Qatar (16)

2020

  1. A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma

    American Journal of Hematology, Vol. 95, Núm. 5, pp. 503-509

  2. Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients

    Leukemia and Lymphoma, Vol. 61, Núm. 8, pp. 1885-1893

2019

  1. Randomized phase III study of alisertib or investigator’s choice (selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma ¨

    Journal of Clinical Oncology

2018

  1. Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients

    British Journal of Haematology, Vol. 180, Núm. 6, pp. 831-839

2017

  1. IgM myeloma: A multicenter retrospective study of 134 patients

    American Journal of Hematology, Vol. 92, Núm. 8, pp. 746-751

  2. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study

    Leukemia, Vol. 31, Núm. 11, pp. 2443-2448

2016

  1. Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice

    American Journal of Hematology, Vol. 91, Núm. 6, pp. 575-580

  2. Daratumumab, bortezomib, and dexamethasone for multiple myeloma

    New England Journal of Medicine, Vol. 375, Núm. 8, pp. 754-766

  3. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy

  4. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Autophagy, Vol. 12, Núm. 1, pp. 1-222

  5. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

2015

  1. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma

    New England Journal of Medicine, Vol. 372, Núm. 2, pp. 142-152

2014

  1. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation

    Journal of Clinical Oncology, Vol. 32, Núm. 6, pp. 587-600

2012

  1. IMWG consensus on maintenance therapy in multiple myeloma

    Blood, Vol. 119, Núm. 13, pp. 3003-3015

  2. Identification of LMO2 transcriptome and interactome in diffuse large B-cell,lymphoma

    Blood, Vol. 119, Núm. 23, pp. 5478-5491

2009

  1. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma

    European Journal of Haematology, Vol. 82, Núm. 6, pp. 426-432